Objectives
The aim of this graduate programme is to train professionals in the field of advanced biotechnologies for personalised medicine, otherwise known as Medicine of the 4 Ps (personalised, preventive, predictive and participatory). Graduates in 'Biotechnologies for Personalised Medicine' must have:
- specialist knowledge and multidisciplinary techniques aimed at developing experimental and translational protocols in the diagnostic and therapeutic fields;
- the skills needed for the application of advanced biotechnology in the new areas required by biotech companies, with particular reference to the development of new devices oriented towards precision medicine;
- a thorough and up-to-date knowledge of the regulations and ethical and bioethical issues associated with the development and use of modern biotechnology;
- the basic skills in the areas of marketing management and regulation, for the proper management of companies and start-ups in the field of modern biotechnology;
- a specialised scientific culture, together with the ability to keep up to date, which are a prerequisite for entry into postgraduate training programmes, such as specialising masters, specialisation schools and doctorates.
Competence
The competences of our graduates include:
- knowledge of the scientific design process in the field of personalised medicine.
- the ability to apply cellular and molecular biotechnological innovations in innovative diagnostic and therapeutic processes.
- knowledge of and ability to use the main methodologies characterising molecular and cellular biotechnologies, also for the design and production of biopharmaceuticals, diagnostics, vaccines and innovative therapies;
- mastery of bioinformatic methodologies for the organisation, construction and access to databases, in particular genomics and proteomics, and the acquisition and distribution of scientific and technological information;
- knowledge and ability to use specific techniques and technologies in areas such as molecular modelling, design and innovative drug design;
- knowledge of the fundamentals of pathological processes of human interest, with reference to their cellular and molecular pathogenetic mechanisms; knowledge of congenital or acquired pathological situations in which it is possible to intervene with a biotechnological approach;
- the ability to design biotechnological protocols to be translated into innovative diagnostic and therapeutic strategies;
- the organisation of development activities in biotechnology companies with a focus on the management, marketing and bioethics aspects in compliance with national and EU regulations in the biotechnology sector.